Yu Kawashima

Yu Kawashima

Auto-generated profile, based on publicly available information

Yu Kawashima

Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
YKYu Kawashima
Yu Kawashima
MHMasayuki Hata
Masayuki Hata
Akio OishiAkio Oishi
Akio Oishi
SOSotaro Ooto
Sotaro Ooto
KYKenji Yamashiro
Kenji Yamashiro
ATAkitaka Tujikawa
Akitaka Tujikawa

1 January 2024 in Retina
Verified
Journal Article
Closed access
YKYu Kawashima
Yu Kawashima
MHMasayuki Hata
Masayuki Hata
MMMasahiro Miyake
Masahiro Miyake
MKMami Kusaka
Mami Kusaka
AOAkio Oishi
Akio Oishi
ATAkitaka Tsujikawa
Akitaka Tsujikawa
Purpose: To investigate the predictors of macular chorioretinal atrophy, consisting of patchy atrophy (PA) at the macula and choroidal neovascularization (CNV)-related macular atrophy (CNV-MA), during treatment with ranibizumab or aflibercept for myopic CNV (mCNV) and its impact on visual outcomes. Methods: This retrospective study included 82 eyes with treatment-naïve mCNV who were treated with pro re nata injections of ranibizumab or aflibercept. Results: Nine eyes (11.0%) presented with macular PA at baseline (PA group), and 73 eyes (89.0%) did not (non-PA group). VA improved during the first year in the non-PA group; a similar trend was noted in the PA group until 3 months after initial treatment. This improvement was maintained until 24 months (P < 0.001) in the non-PA group, but not in the PA group. In the PA group, macular chorioretinal atrophy progressed faster (P < 0.0001), and CNV-MA was more frequent during the 2 years of treatments (P = 0.04). Even non-PA group eyes sometimes developed CNV-MA (42% at Month 24) if they had a larger CNV and thinner subfoveal choroidal thickness at baseline, resulting in poorer visual prognosis (P < 0.01). Conclusion: Macular PA at baseline was a risk factor for CNV-MA development and was associated with poor visual outcomes.